Research Highlights:
- Researchers in Finland found a link between smoking and subarachnoid hemorrhage (SAH), a type of bleeding stroke, in a study of more than 16,000 pairs of twins over 42 years.
- The study found that bleeding in the brain can be explained to a greater degree by environmental risk factors, such as smoking, than by genetic influence.
Embargoed until 4 a.m. CT/5 a.m. ET Thursday, September 17, 2020
DALLAS, September 17, 2020 — An investigation of the Finnish Twin Cohort reaffirmed a link between smoking and subarachnoid hemorrhage (SAH), a type of bleeding stroke that occurs under the membrane that covers the brain and is frequently fatal. The new study by researchers in Finland is published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.
In a 2010 study of nearly 80,000 twins from Denmark, Finland and Sweden, results suggested that SAH had more to do with external risk factors and very little to do with genetic influence. Twins share either all or half their genes (identical vs. fraternal) so they are valuable for studies designed to evaluate the role of genetics versus environmental factors in disease development.
In this study, researchers sought to clarify the factors involved when only one twin suffered from fatal bleeding in the brain and hypothesized that smoking – the most important environmental risk factor – could play a significant role. This study utilized health care data from the Finnish Twin Cohort, a national database of 32,564 individuals (16,282 same-sex, twin pairs in Finland) who were born before 1958 and alive in 1974, and followed for over 42 years between 1976 and 2018. Researchers identified 120 fatal bleeding stroke events among the twins, and the strongest link for a fatal brain bleed was found among smokers.
“Our study provides further evidence about the link between smoking and bleeding in the brain,” said corresponding researcher Ilari Rautalin, B.M., a sixth-year medical and Ph.D. student at the University of Helsinki in Finland.
Data collected from surveys included smoking; high blood pressure (diagnosis or use of antihypertensive medications); physical activity; body mass index; education; and alcohol use. Participants were separated into two groups: smokers (occasional or current) or non-smokers (never and former). Current smokers were classified according to the number of cigarettes smoked per day: light, less than 10; moderate, 10-19; heavy, 20 or more.
The analysis of the 120 fatal bleeding events found:
- Four fatalities occurred among both twins in two pairs. In the remaining 116 fatalities, one twin died of bleeding in the brain, while the other died of another cause, migrated during the follow-up or was still alive at the end of the study follow-up.
- Heavy and moderate smokers had 3 times the risk of fatal bleeding in the brain, while light smokers had slightly less at 2.8 times the risk.
- Median age at the fatal brain bleed was 61.4 years.
Risk factors such as high blood pressure, lower physical activity rates and being female were not found to be significant influences in this investigation, unlike prior studies. Smoking was associated with fatal bleeding in the brain consistently in both men and women and with bleeding stroke deaths within twin pairs where only one of the twins died from a SAH.
The current study did not have data on non-fatal SAH events and researchers were not able to estimate the impact of former smoking on these brain bleeds. Former smokers and never smokers were combined in the non-smoking category. Researchers were also not able to confirm the aneurysmal origin of SAHs (no patient data was available) and may have included a few non-aneurysmal SAH events.
“This long-term study in twins helps to confirm the link between subarachnoid hemorrhage and smoking,” said Rose Marie Robertson, M.D., FAHA, the American Heart Association’s deputy chief science and medical officer and co-director of the AHA Tobacco Center for Regulatory Science, who was not involved in the study. “Not smoking or quitting if you’ve already started, is an essential component of primary prevention.”
Co-authors are Miikka Korja, M.D., Ph.D.; and Jaakko Kaprio, M.D., Ph.D. No disclosures were reported.
The Aarne and Aili Turunen Foundation; the Paulo Foundation; the Aarne Koskelo Foundation; and the Academy of Finland Centre of Excellence in Complex Disease Genetics funded the study.
Additional Resources:
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information
About the American Stroke Association
The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit stroke.org. Follow us on Facebook and Twitter.
###
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Karen Astle: 214-706-1392, karen.astle@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Leave a Reply